#### Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

		ugai i ili	ng. Aar			IOAL	-0 114				
AGIOS PH Form 4 June 25, 20	ARMACEUTICA 14	ALS INC									
FORM	ЛД								OMB AF	PPROVAL	
	UNITED	STATES			AND EXCH , D.C. 2054		GE CO	OMMISSION	OMB Number:	3235-0287	
Check the check	nger								Expires:	January 31, 2005	
subject Section Form 4	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Estimated average burden hours per				
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction 1(c) See Instruction 1(c)									0.0		
(Print or Type	Responses)										
	Address of Reporting	Symbol		d Ticker or Tra	-	5. Relationship of Reporting Person(s) to Issuer					
	AGIOS PHARMACEUTICALS INC [AGIO]					(Check all applicable)					
			3. Date of Earliest Transaction (Month/Day/Year)					Director 10% Owner Officer (give title Other (specify below) below)			
29 NEWBURY STREET, 3RD 06/24/2014 below) below) below)											
				Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line)			
BOSTON, MA 02116 Form filed by More than One Reporting Person Person Person											
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Sec	urities	s Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		n Date, if	3. Transactio Code (Instr. 8)	Fransactioner Disposed of (D)Code(Instr. 3, 4 and 5)				6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)		
Common Stock	06/24/2014			J <u>(1)</u>	1,669,324	D	\$0	3,895,090	D (2)		
Common Stock	06/24/2014			J <u>(3)</u>	122,554	А	\$0	122,554	D (4)		
Common Stock	06/24/2014			J <u>(5)</u>	122,554	D	\$0	0	D (4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of<br/>information contained in this form are not<br/>required to respond unless the formSEC 1474<br/>(9-02)

1

#### Edgar Filing: AGIOS PHARMACEUTICALS INC - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. 6. Date Exerce onNumber Expiration Date of (Month/Day/Y) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title Amound Underly Securiti (Instr. 3	t of ying ies	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	o Title N o	Amount or Number of Shares		

### **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationsh			
	Director	10% Owner	Officer	Other	
THIRD ROCK VENTURES LP 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		Х			
Third Rock Ventures GP, L.P. 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		Х			
TRV GP, LLC 29 NEWBURY STREET, 3RD FLOOR BOSTON, MA 02116		Х			
Signatures					
/s/ Kevin Gillis, Chief Financial Officer of Ventures GP, L.P., general partner of Thir			-	ner of Third Rock	06/25/2014

**Signature of Reporting Person	Date				
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P.					
**Signature of Reporting Person	Date				
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC	06/25/2014				
**Signature of Reporting Person	Date				

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Distribution of shares in kind by Third Rock Ventures, L.P. ("TRV") on a pro rata basis to its partners.

The shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of

- (2) TRV GP is TRV GP, LLC ("TRV GP LLC") and, as such, each of TRV GP and TRV GP LLC exercises shared voting and investment power over the shares held of record by TRV. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
- (3) TRV GP received shares distributed in kind by TRV on a pro rata basis to its partners.

The shares are directly held by TRV GP. As such, TRV GP LLC exercises voting and investment power over the shares held of record by(4) TRV GP. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

(5) Distribution of shares in kind by TRV GP on a pro rata basis to its partners.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.